When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Current health news briefs cover potential risks linked to Novo Nordisk's diabetes drug Ozempic, opposition to Robert F.

If coverage is structured properly, it could greatly help our country's chronic disease and obesity epidemics. But Donald Trump's Food and Drug Administration (FDA) will also need to ensure the drugs ...

The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for ...

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

Here are five things to know about GLP-1s and increased healthcare utilization: 1. According to the report, an uptick in GLP-1 use is facilitating a range of "crucial preventive care," including pap ...

The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...

Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...

Novo Nordisk (NVO) is making headlines with its inventive investment of $1.2 billion aimed at building a new production ...

Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance ...

Study confirms link between Ozempic's active ingredient and low risk of vision loss. Ophthalmology organizations recommend continued use.